I initiate coverage on Haleon with a "hold" rating due to decent results and potential for ongoing growth, despite a slight revenue slip last year. Haleon's dividend grew 10% and is well-covered ...

Haleon to invest $54 mln in US R&D centre to ... invest $54 million in its global research and development centre in Richmond, U.S., aiming to boost its pipeline for new product innovations.

Consumer healthcare giant Haleon has reported a strong financial performance for 2024, with organic revenue growth of five per cent. However, revenue declined by 0.6 per cent on a reported basis ...

Shares of HLN opened at $10.45 on Wednesday. Haleon has a 12 month low of $7.89 and a 12 month high of $10.80. The company has a 50-day moving average price of $9.66 and a two-hundred day moving ...

In this article, we are going to take a look at where Haleon plc (NYSE:HLN) stands against other stocks that lead Monday’s charge amid market bloodbath. The stock market kicked off the trading ...

Haleon is one of the largest consumer healthcare companies in the world. Over the last few years, Haleon has achieved a more rationalized operation by divesting multiple non-strategic brands ...

Haleon reported FY24 revenue of £11.23B ($14.19B), down 0.6%, with 5% organic growth. Adjusted operating profit fell 6.5% to £2.50B. 2025 guidance projects 4-6% organic revenue growth, with ...

In this article, we are going to take a look at where Haleon plc (NYSE:HLN) stands against the other pharma stocks. Healthcare, which includes numerous businesses that offer patient care ...